Muscle autoantibodies in myasthenia gravis: Beyond diagnosis?

Expert Review of Clinical Immunology

Volumn 8, Issue 5, 2012, Pages 427-438

  Meriggioli, Matthew N ^a   Sanders, Donald B ^b  

^a UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

AChR; biomarkers; diagnosis; MuSK; myasthenia gravis

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; CONNECTIN; LIPOPROTEIN RECEPTOR; LIPOPROTEIN RELATED PROTEIN RECEPTOR 4; MUSCLE ANTIBODY; MUSCLE SPECIFIC TYROSINE KINASE; PREDNISONE; PROTEIN ANTIBODY; PROTEIN TYROSINE KINASE; RYANODINE; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ANTIBODY TITER; DISEASE SEVERITY; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PROGNOSIS; PROTEIN LOCALIZATION; REGULATORY T LYMPHOCYTE; REVIEW; SENSITIVITY AND SPECIFICITY; SYNAPTIC TRANSMISSION; THYMECTOMY; THYMOMA; THYMUS; TREATMENT RESPONSE;

AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; HUMANS; MUSCLE, SKELETAL; MYASTHENIA GRAVIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; RECEPTORS, NICOTINIC;

EID: 84864984950     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.12.34     Document Type: Review

References (105)

1. Phillips LH 2nd. The epidemiology of myasthenia gravis. Ann. NY Acad. Sci. 998, 407-412 (2003
2. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: Emerging clinical and biological heterogeneity. Lancet Neurol. 8(5), 475-490 (2009
3. Drachman DB. Myasthenia gravis. N. Engl. J. Med. 330(25), 1797-1810 (1994
4. Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science 180(4088), 871-872 (1973
5. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Autoantibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat. Med. 7(3), 365-368 (2001
6. McConville J, Farrugia ME, Beeson D et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann. Neurol. 55(4), 580-584 (2004
7. Leite MI, Jacob S, Viegas S et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 131(Pt 7), 1940-1952 (2008
8. Romi F, Skeie GO, Aarli JA, Gilhus NE. Muscle autoantibodies in subgroups of myasthenia gravis patients. J. Neurol. 247(5), 369-375 (2000
9. Drachman DB, Adams RN, Stanley EF, Pestronk A. Mechanisms of acetylcholine receptor loss in myasthenia gravis. J. Neurol. Neurosurg. Psychiatr. 43(7), 601-610 (1980
10. Toyka KV, Drachman DB, Griffin DE et al. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N. Engl. J. Med. 296(3), 125-131 (1977
11. Lefvert AK. Immunoglobulins in myasthenia gravis. Kinetic properties of the acetylcholine-receptor antibody studied during lymph drainage. Clin. Exp. Immunol. 34(1), 111-117 (1978
12. Newsom-Davis J, Pinching AJ, Vincent A, Wilson SG. Function of circulating antibody to acetylcholine receptor in myasthenia gravis: Investigation by plasma exchange. Neurology 28(3), 266-272 (1978
13. Lindstrom J. An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis. Clin. Immunol. Immunopathol. 7(1), 36-43 (1977
14. Tzartos SJ, Lindstrom JM. Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits. Proc. Natl Acad. Sci. USA 77(2), 755-759 (1980
15. Gomez AM, Van Den Broeck J, Vrolix K et al. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Autoimmunity 43(5-6), 353-370 (2010
16. Willcox N, Leite MI, Kadota Y et al. Autoimmunizing mechanisms in thymoma and thymus. Ann. NY Acad. Sci. 1132, 163-173 (2008
17. Schluep M, Willcox N, Vincent A, Dhoot GK, Newsom-Davis J. Acetylcholine receptors in human thymic myoid cells in situ: An immunohistological study. Ann. Neurol. 22(2), 212-222 (1987
18. Morgenthaler TI, Brown LR, Colby TV, Harper CM Jr, Coles DT. Thymoma. Mayo Clin. Proc. 68(11), 1110-1123 (1993
19. Aarli J. Myasthenia gravis and thymoma. In: Handbook of Myasthenia Gravis and Myasthenic Syndromes. Lisak RP (Ed.). Marcel Dekker, Inc., NY, USA, 207-224.
20. Heidenreich F, Vincent A, Willcox N, Newsom-Davis J. Anti-acetylcholine receptor antibody specificities in serum and in thymic cell culture supernatants from myasthenia gravis patients. Neurology 38(11), 1784-1788 (1988
21. Gilhus NE, Aarli JA, Matre R. Myasthenia gravis: The specificities of skeletal muscle and thymus antibodies. Acta Neurol. Scand. 68(5), 328-336 (1983
22. Hohlfeld R, Kalies I, Kohleisen B, Heininger K, Conti-Tronconi B, Toyka KV. Myasthenia gravis: Stimulation of antireceptor autoantibodies by autoreactive T cell lines. Neurology 36(5), 618-621 (1986
23. Melms A, Schalke BC, Kirchner T, Müller-Hermelink HK, Albert E, Wekerle H. Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients. J. Clin. Invest. 81(3), 902-908 (1988
24. Sommer N, Willcox N, Harcourt GC, Newsom-Davis J. Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells. Ann. Neurol. 28(3), 312-319 (1990
25. Sommer N, Harcourt GC, Willcox N, Beeson D, Newsom-Davis J. Acetylcholine receptor-reactive T lymphocytes from healthy subjects and myasthenia gravis patients. Neurology 41(8), 1270-1276 (1991
26. Mygland A, Vincent A, Newsom-Davis J et al. Autoantibodies in thymomaassociated myasthenia gravis with myositis or neuromyotonia. Arch. Neurol. 57(4), 527-531 (2000
27. Kadota Y, Okumura M, Miyoshi S et al. Altered T cell development in human thymoma is related to impairment of MHC class II transactivator expression induced by interferon-gamma (IFN-gamma). Clin. Exp. Immunol. 121(1), 59-68 (2000
28. Scarpino S, Di Napoli A, Stoppacciaro A et al. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin. Exp. Immunol. 149(3), 504-512 (2007
29. Ströbel P, Rosenwald A, Beyersdorf N et al. Selective loss of regulatory T cells in thymomas. Ann. Neurol. 56(6), 901-904 (2004
30. Howard FM Jr, Lennon VA, Finley J, Matsumoto J, Elveback LR. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann. NY Acad. Sci. 505, 526-538 (1987
31. Lindstrom J. An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis. Clin. Immunol. Immunopathol. 7(1), 36-43 (1977
32. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26(11), 1054-1059 (1976
33. Lefvert AK, Bergström K, Matell G, Osterman PO, Pirskanen R. Determination of acetylcholine receptor antibody in myasthenia gravis: Clinical usefulness and pathogenetic implications. J. Neurol. Neurosurg. Psychiatr. 41(5), 394-403 (1978
34. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: Results in 153 validated cases and 2967 diagnostic assays. J. Neurol. Neurosurg. Psychiatr. 48(12), 1246-1252 (1985
35. Agius MA, Richman DP, Vincent A. Autoantibody testing in the diagnosis and management of autoimmune disorders of neuromuscular transmission and related disorders. In: Myasthenia Gravis and Related Disorders (2nd Edition). Kaminski HJ (Ed.). Humana Press, NJ, USA, 143-156 (2009
36. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles. Clin. Exp. Immunol. 49(2), 257-265 (1982
37. Lefvert AK, Björkholm M. Antibodies against the acetylcholine receptor in hematologic disorders: Implications for the development of myasthenia gravis after bone marrow grafting. N. Engl. J. Med. 317(3), 170 (1987
38. Lennon VA. Serological diagnosis of myasthenia gravis and Lambert-Eaton myasthenic syndrome. In: Handbook of Myasthenia Gravis and Myasthenic Syndromes. Lisak RP (Ed.). Marcel Dekker, NY, USA, 149-164 (1994
39. McKeon A, Lennon VA, Jacob A et al. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve 39(1), 87-90 (2009
40. Chan KH, Lachance DH, Harper CM, Lennon VA. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve 36(5), 651-658 (2007
41. Vernino S, Lennon VA. Autoantibody profiles and neurological correlations of thymoma. Clin. Cancer Res. 10(21), 7270-7275 (2004
42. Tindall RS. Humoral immunity in myasthenia gravis: Biochemical characterization of acquired antireceptor antibodies and clinical correlations. Ann. Neurol. 10(5), 437-447 (1981
43. Jaretzki A 3rd, Barohn RJ, Ernstoff RM et al. Myasthenia gravis: Recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55(1), 16-23 (2000
44. Besinger UA, Toyka KV, Hömberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 33(10), 1316-1321 (1983
45. Oosterhuis HJ, Limburg PC, Hummel-Tappel E, The TH. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients. J. Neurol. Sci. 58(3), 371-385 (1983
46. Oosterhuis HJ, Limburg PC, Hummel-Tappel E, Van den Burg W, The TH. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 3. The effect of thymectomy. J. Neurol. Sci. 69(3), 335-343 (1985
47. Tindall RS. Humoral immunity in myasthenia gravis: Effect of steroids and thymectomy. Neurology 30(5), 554-557 (1980
48. Vincent A, Newsom-Davis J, Newton P, Beck N. Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis. Neurology 33(10), 1276-1282 (1983
49. Zong Y, Zhang B, Gu S et al. Structural basis of agrin-LRP4-MuSK signaling. Genes Dev. 26(3), 247-258 (2012
50. Punga AR, Lin S, Oliveri F, Meinen S, Rüegg MA. Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice. Exp. Neurol. 230(2), 207-217 (2011
51. Shiraishi H, Motomura M, Yoshimura T et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibodypositive myasthenia gravis. Ann. Neurol. 57(2), 289-293 (2005
52. Cole RN, Reddel SW, Gervásio OL, Phillips WD. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann. Neurol. 63(6), 782-789 (2008
53. Shigemoto K, Kubo S, Maruyama N et al. Induction of myasthenia by immunization against muscle-specific kinase. J. Clin. Invest. 116(4), 1016-1024 (2006
54. Jha S, Xu K, Maruta T et al. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J. Neuroimmunol. 175(1-2), 107-117 (2006
55. ter Beek WP, Martínez-Martínez P, Losen M et al. The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates. Am. J. Pathol. 175(4), 1536-1544 (2009
56. Lavrnic D, Losen M, Vujic A et al. The features of myasthenia gravis with autoantibodies to MuSK. J. Neurol. Neurosurg. Psychiatr. 76(8), 1099-1102 (2005
57. Mori S, Kubo S, Akiyoshi T et al. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am. J. Pathol. 180(2), 798-810 (2012
58. Mori S, Yamada S, Kubo S et al. Divalent and monovalent autoantibodies cause dysfunction of MuSK by distinct mechanisms in a rabbit model of myasthenia gravis. J. Neuroimmunol. 244(1-2), 1-7 (2012
59. Klooster R, Plomp JJ, Huijbers MG et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 135(Pt 4), 1081-1101 (2012
60. Kawakami Y, Ito M, Hirayama M et al. Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology 77(20), 1819-1826 (2011
61. Hatanaka Y, Hemmi S, Morgan MB et al. Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibodypositive MG. Neurology 65(9), 1508-1509 (2005
62. Zhu D, Yang Z, Luo Z, Luo S, Xiong WC, Mei L. Muscle-specific receptor tyrosine kinase endocytosis in acetylcholine receptor clustering in response to agrin. J. Neurosci. 28(7), 1688-1696 (2008
63. Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts. Muscle Nerve 44(1), 36-40 (2011
64. Evoli A, Tonali PA, Padua L et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126(Pt 10), 2304-2311 (2003
65. Ohta K, Shigemoto K, Kubo S et al. MuSK antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG. Neurology 62(11), 2132-2133 (2004
66. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 60(12), 1978-1980 (2003
67. Suzuki S, Utsugisawa K, Nagane Y, Satoh T, Kuwana M, Suzuki N. Clinical and immunological differences between early and late-onset myasthenia gravis in Japan. J. Neuroimmunol. 230(1-2), 148-152 (2011
68. Sanders DB, Juel VC. MuSK-antibody positive myasthenia gravis: Questions from the clinic. J. Neuroimmunol. 201-202, 85-89 (2008
69. Leite MI, Ströbel P, Jones M et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann. Neurol. 57(3), 444-448 (2005
70. Bartoccioni E, Scuderi F, Minicuci GM, Marino M, Ciaraffa F, Evoli A. Anti-MuSK antibodies: Correlation with myasthenia gravis severity. Neurology 67(3), 505-507 (2006
71. Niks EH, van Leeuwen Y, Leite MI et al. Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. J. Neuroimmunol. 195(1-2), 151-156 (2008
72. Strauss AJ, Kemp PG Jr. Serum autoantibodies in myasthenia gravis and thymoma: Selective affinity for I-bands of striated muscle as a guide to identification of antigen(s). J. Immunol. 99(5), 945-953 (1967
73. Marx A, Willcox N, Leite MI et al. Thymoma and paraneoplastic myasthenia gravis. Autoimmunity 43(5-6), 413-427 (2010
74. Romi F, Gilhus NE, Varhaug JE, Myking A, Skeie GO, Aarli JA. Thymectomy and anti-muscle autoantibodies in late-onset myasthenia gravis. Eur. J. Neurol. 9(1), 55-61 (2002
75. Wang K, McClure J, Tu A. Titin: Major myofibrillar components of striated muscle. Proc. Natl Acad. Sci. USA 76(8), 3698-3702 (1979
76. Yamamoto AM, Gajdos P, Eymard B et al. Anti-titin antibodies in myasthenia gravis: Tight association with thymoma and heterogeneity of nonthymoma patients. Arch. Neurol. 58(6), 885-890 (2001
77. Romi F, Skeie GO, Aarli JA, Gilhus NE. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Arch. Neurol. 57(11), 1596-1600 (2000
78. Skeie GO, Mygland A, Aarli JA, Gilhus NE. Titin antibodies in patients with late onset myasthenia gravis: Clinical correlations. Autoimmunity 20(2), 99-104 (1995
79. Romi F, Skeie GO, Vedeler C, Aarli JA, Zorzato F, Gilhus NE. Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis. A study of IgG subclasses and clinical correlations. J. Neuroimmunol. 111(1-2), 169-176 (2000
80. Skeie GO, Aarli JA, Matre R et al. Titin antibody positive myasthenia gravis patients have a cellular immune response against the main immunogenic region of titin. Eur. J. Neurol. 4, 131-137 (1997
81. Romi F, BøL, Skeie GO, Myking A, Aarli JA, Gilhus NE. Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. J. Neuroimmunol. 128(1-2), 82-89 (2002
82. Skeie GO, Freiburg A, Kolmerer B et al. Titin transcripts in thymomas. J. Autoimmun. 10(6), 551-557 (1997
83. Coronado R, Morrissette J, Sukhareva M, Vaughan DM. Structure and function of ryanodine receptors. Am. J. Physiol. 266(6 Pt 1), C1485-C1504 (1994
84. Mygland A, Aarli JA, Matre R, Gilhus NE. Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis. J. Neurol. Neurosurg. Psychiatr. 57(7), 843-846 (1994
85. Romi F, Aarli JA, Gilhus NE. Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. Eur. J. Neurol. 14(6), 617-620 (2007
86. Mygland A, Tysnes OB, Aarli JA, Matre R, Gilhus NE. IgG subclass distribution of ryanodine receptor autoantibodies in patients with myasthenia gravis and thymoma. J. Autoimmun. 6(4), 507-515 (1993
87. Skeie GO, Mygland A, Treves S, Gilhus NE, Aarli JA, Zorzato F. Ryanodine receptor antibodies in myasthenia gravis: Epitope mapping and effect on calcium release in vitro. Muscle Nerve 27(1), 81-89 (2003
88. Mygland A, Tysnes OB, Matre R, Aarli JA, Gilhus NE. Anti-cardiac ryanodine receptor antibodies in thymoma-associated myasthenia gravis. Autoimmunity 17(4), 327-331 (1994
89. Skeie GO, Lunde PK, Sejersted OM, Mygland A, Aarli JA, Gilhus NE. Myasthenia gravis sera containing antiryanodine receptor antibodies inhibit binding of [3H]-ryanodine to sarcoplasmic reticulum. Muscle Nerve 21(3), 329-335 (1998
90. Ohta M, Ohta K, Itoh N, Kurobe M, Hayashi K, Nishitani H. Anti-skeletal muscle antibodies in the sera from myasthenic patients with thymoma: Identification of anti-myosin, actomyosin, actin, and alpha-actinin antibodies by a solid-phase radioimmunoassay and a western blotting analysis. Clin. Chim. Acta 187(3), 255-264 (1990
91. Yamamoto T, Sato T, Sugita H. Antifilamin, antivinculin, and antitropomyosin antibodies in myasthenia gravis. Neurology 37(8), 1329-1333 (1987
92. Skeie GO, Romi F. Paraneoplastic myasthenia gravis: Immunological and clinical aspects. Eur. J. Neurol. 15(10), 1029-1033 (2008
93. Suzuki S, Utsugisawa K, Yoshikawa H et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch. Neurol. 66(11), 1334-1338 (2009
94. Suzuki S, Utsugisawa K, Nagane Y, Suzuki N. Three types of striational antibodies in myasthenia gravis. Autoimmune Dis. 2011, 740583 (2011
95. Suzuki S, Satoh T, Yasuoka H et al. Novel autoantibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis. J. Neuroimmunol. 170(1-2), 141-149 (2005
96. Romi F, Suzuki S, Suzuki N, Petzold A, Plant GT, Gilhus NE. Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis. J. Neurol. 259(7), 1312-1316 (2011
97. Agius MA, Zhu S, Kirvan CA et al. Rapsyn antibodies in myasthenia gravis. Ann. NY Acad. Sci. 841, 516-521 (1998
98. Agius MA, Zhu S, Aarli JA. Antirapsyn antibodies occur commonly in patients with lupus. Ann. NY Acad. Sci. 841, 525-526 (1998
99. Phillips TM, Manz HJ, Smith FA, Jaffe HA, Cohan SL. The detection of anti-cholinesterase antibodies in myasthenia gravis. Ann. NY Acad. Sci. 377, 360-371 (1981
100. Geen J, Howells RC, Ludgate M, Hullin DA, Hogg SI. The prevalence of antiacetylcholinesterase antibodies in autoimmune disease. Autoimmunity 37(8), 579-585 (2004
101. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to lowdensity lipoprotein receptor-related protein 4 in myasthenia gravis. Ann. Neurol. 69(2), 418-422 (2011
102. Pevzner A, Schoser B, Peters K et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J. Neurol. 259(3), 427-435 (2012
103. Zhang B, Tzartos JS, Belimezi M et al. Autoantibodies to lipoprotein-related protein 4 in patients with doubleseronegative myasthenia gravis. Arch. Neurol. 69(4), 445-451 (2012
104. Yang L, Maxwell S, Leite MI et al. Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China. J. Neurol. Sci. 301(1-2), 71-76 (2011
105. Papp K, Prechl J. The use of antigen microarrays in antibody profiling. Methods Mol. Biol. 815, 175-185 (2012